BCHE and early-onset autosomal dominant Alzheimer disease: Due to the selective and potent BChE inhibition shown by certain derivatives, these molecules hold promise as lead candidates in the development of new therapeutics for neurodegenerative disorders, especially Alzheimer’s disease, where BChE-targeting drugs are particularly relevant in the late stages.